Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. (MEDXF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
medxf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Medexus Pharmaceuticals Inc.You MEDXF | $90M | N/A | — | — |
 Decibel Cannabis Company Inc. DBCCF | $46M | N/A | — | -$0.01 |
 Earth Science Tech, Inc. ETST | $52M | 11.66x | -64.4% | $0.01 |
 Flower One Holdings Inc. FLOOF | $0M | N/A | — | -$0.06 |
 1CM Inc. MILFF | $17M | 53.87x | +64.4% | $0.00 |
Industry Average 2 peers with valid PE | — | 32.77x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Medexus Pharmaceuticals Inc. (MEDXF) measures how much investors pay for each dollar of the company's trailing earnings. MEDXF's current PE ratio of N/A is calculated by dividing its stock price of $2.78 by its TTM earnings per share of —.
Frequently asked questions
MEDXF pe ratio · 6 questionsMEDXF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.78 and TTM EPS of —. Data sourced from Financial Modeling Prep via MEDXF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Medexus Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09